

PRESS RELEASE

1 December 2016

Recipharm and Laccure agree commercial collaboration

Leading contract development and manufacturing organisation (CDMO) Recipharm is entering into a collaboration with Laccure AB for the commercial manufacture and delivery of Laccure® Pessary.

The new product, which has been developed to help women suffering from bacterial vaginosis, will be manufactured, packaged and distributed globally from Recipharm's facility in Karlskoga that specialises in the production of semi-solid products.

Over the past years, Laccure AB has successfully taken the product from innovation through clinical studies to commercial manufacturing. The development work was focused on creating a highly effective antibiotic-free product that was also user-friendly in terms of being easy to apply and not messy to use.

Recipharm and Laccure AB have now signed an agreement for commercial production of Laccure® Pessary and the exact date for the launch will be announced next year.

Laccure AB is a project company within the life science development organisation Partners for Development Investments in Life Sciences (P.U.L.S.). As it prepares for launch, the owner is endeavouring to sell the company to a buyer with the substantial resources required to bring the product to market.

Jeanette Robertsson, CEO of Laccure AB, said: "We are delighted to be collaborating with Recipharm, they are an expert partner that we can rely on for the commercial supply of our new product.

"Given the potential market for the product, a major benefit of partnering with Recipharm is that they have a high level of production capacity, which of course gives us the possibility to further scale up the batch size to meet market requirements in the future."

It is estimated that more than 300 million women throughout the world suffer from bacterial vaginosis every year however, there are currently no effective and safe products available that are also user-friendly and can be used with low frequency dosages.

Laccure® Pessary is based on a patented substance that releases lactic acid, and only needs to be administered once to treat a bacterial vaginosis infection and then once a month to prevent a recurrence.

Ingela Palmkvist, General Manager at Recipharm in Karlskoga, said: "We are really looking forward to the commercial launch of this product, and contributing to something that will make a major difference to the lives of many women across the globe."

Contact information

Ingela Palmkvist, General Manager, ingela.palmqvist@recipharm.com, +46 (0)8 602 52 00
Erik Haeffler, Vice President Manufacturing Services & Head of CSR, erik.haeffler@recipharm.com,
+ 46 (0) 8 6025 285

Sven-Inge Svensson, Chairman of the board, Laccure AB, sven-inge.svensson@laccure.com
Jeanette Robertsson, CEO, Laccure AB, jeanette.robertsson@laccure.com

For media enquiries, please contact Lindsay Baldry at ramarketing: lindsay@ramarketingpr.com,
+ 44 (0)191 222 1242, ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr,
LinkedIn: /ramarketing

About Recipharm

Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) (in the pharmaceutical industry employing around 3,500 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's turnover is approximately SEK 5.0 billion and the Company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.

For more information on Recipharm and its services, please visit www.recipharm.com

About Laccure

Laccure AB was founded in 2007 and is based in Helsingborg. Laccure is a project company within the life science development company P.U.L.S. (Partners for Development Investments in Life Sciences). The initial development of the company's product was carried out at Lund University in Sweden and the University of Gdansk in Poland. Further pharmaceutical development and GMP manufacturing for preclinical and clinical studies was performed in collaboration with a number of contract research companies. Laccure AB is certified according to ISO13485 and the product is CE-marked.

For further information visit www.laccure.com and www.pulsinvest.se